Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting As Indolent Lymphoma

Last updated: February 7, 2025
Sponsor: Azienda Unita Sanitaria Locale Reggio Emilia
Overall Status: Active - Recruiting

Phase

N/A

Condition

Lymphoma, B-cell

Lymphoma

Treatment

N/A

Clinical Study ID

NCT06822829
446/2023/OSS/IRCCSRE
  • Ages > 18
  • All Genders

Study Summary

Most relapses of diffuse large B-cell lymphoma (DLBCL) occur as high-grade lymphoma within the first two years after diagnosis. Relapses as indolent lymphoma are rare events, and the true incidence of this phenomenon is unknown, since literature data are scarce/ and usually restricted to case reports. Analogously, reported treatment strategies are rather heterogeneous, since no standard of care is established and advanced age together with previous anthracycline exposure may narrow the therapeutic choice.

The goal of this observational study is to assess epidemiological, clinical characteristics and survival of diffuse large b-cell lymphoma (DLBCL) relapsing as indolent lymphoma.

More precisely, the study aims at identifying diagnostic and imaging features associated with relapse as indolent lymphoma and at evaluating disease response to selected therapies.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age 18 years or older at the time of diagnosis.

  • Previous diagnosis of diffuse large B-cell lymphoma with/without a discordantcomponent of indolent B-cell lymphoma, or previous diagnosis of diffuse large B-celllymphoma transformed from indolent B-cell lymphoma.

  • First-line treatment for diffuse large B-cell lymphoma.

  • Histologically documented relapse of indolent B-cell lymphoma, diagnosed between 2010 and 2020.

  • Availability of the histological report of the relapse.

  • Availability of clinical and laboratory data related to both the initial diagnosisand relapse.

  • Availability of follow-up data.

  • Consent to participate in the study and signing of the specific informed consentform (for living and/or contactable patients).

Exclusion

Exclusion Criteria:

  • None

Study Design

Total Participants: 50
Study Start date:
August 19, 2024
Estimated Completion Date:
August 31, 2026

Connect with a study center

  • Azienda USL IRCCS di Reggio Emilia

    Reggio Emilia,
    Italy

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.